ReviewOncoTargets and therapy2018
Combined small-cell lung carcinoma.
Review in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Guideline
- Surgical resection reveals combined small-cell lung carcinoma and adenocarcinoma with dual epidermal growth factor receptor and anaplastic lymphoma kinase alterations following neoadjuvant chemotherapy: A rare case.SAGE open medical case reports · 2026Article
- Article
- Combined small-cell lung cancer with adenocarcinoma: a rare case and literatures review.Journal of cancer research and clinical oncology · 2025Review
- Challenges of small cell lung cancer heterogeneity and phenotypic plasticity.Nature reviews. Cancer · 2025Review
- Review
- Review
- Machine learning-driven prognostic prediction model for composite small cell lung cancer: identifying risk factors with network tools and validation using SEER data and external cohorts.Frontiers in oncology · 2025Article
- Case Report: Pathological diagnosis of left upper lobe nodules: two cases of composite small cell lung cancer and literature review.Frontiers in oncology · 2025Article
- Case Report: Mimicking benignity: hepatic sinusoidal metastasis masquerading as diffuse liver disease in small cell lung cancer.Frontiers in oncology · 2025Article
- The therapeutic effect of DX2 inhibition in nicotine-induced lung cancer progression.Molecular therapy. Oncology · 2024Article
- Risk factors and nomograms for diagnosis and early death in patients with combined small cell lung cancer with distant metastasis: a population-based study.The Journal of international medical research · 2024Article
- Article
- Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report.The American journal of case reports · 2024Article
- Genomic and transcriptomic profiling of combined small-cell lung cancer through microdissection: unveiling the transformational pathway of mixed subtype.Journal of translational medicine · 2024Article
- Clinical features and prognostic factors of IV combined small cell lung cancer: A propensity score matching analysis.PloS one · 2024Article
- Assessment of the relationship between miR-499C/T (rs3746444) polymorphism and lung carcinoma in Iranian population; a case-control study.African health sciences · 2023Article
- Transformation ofTranslational lung cancer research · 2023Article
- Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report.World journal of clinical cases · 2023Article
- Clinicopathological and Treatment Patterns of Combined Small-Cell Lung Carcinoma with Future Insight to Treatment: A Population-Based Study.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, studies assessing combined small-cell lung carcinoma (C-SCLC) are relatively scarce and limited. Indeed the clinicopathological features, treatment, and prognosis of patients with C-SCLC have not been fully determined. The incidence of C-SCLC ranges from 5%-28% in different studies, which is related to the specimen types used. The clinical features of C-SCLC are characterized by the higher proportion of peripheral locations, earlier stage, and more opportunity to experience surgery. Surgery is more important for earlier stage C-SCLC. There have been no recent changes in the chemotherapy of C-SCLC, which is recommended by the treatment guidelines for SCLC, neither showing survival benefit from the 3-agent regimen. Meanwhile, the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in EGFR-mutated C-SCLC patients remains inconclusive. This review focuses on clinical and pathologic features, prognostic factors, and optimized treatment model in C-SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.